{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:12:45Z","timestamp":1768432365091,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"vor","delay-in-days":81,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      There is no reported data for patients with malignant bladder Botox\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injection related outcomes. Herein, we reported effect of Botox\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injection in case of BCG cystitis. In addition, reporting of rare incidence of both primary neuroendocrine differentiation of bladder tumor and primary ovarian paraganglioma post cystectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Presentation of case:<\/jats:title>\n                    <jats:p>\n                      A-64 years old female presented with sever irritative lower urinary tract symptoms (LUTS) post vesical BCG installation for carcinoma in situ. Patient's symptoms were relieved after Botox\n                      <jats:sup>\u00ae<\/jats:sup>\n                      bladder injection after anticholinergics failure. One year later, she came back with hematuria. Cystoscopy showed nodular bladder lesion. Hypertension episodes were noticed during cystoscopic resection. Pathological examination showed presence of muscle invasive transitional cell carcinoma (TCC) with neuroendocrine differentiation. Patient underwent radical cystectomy and pathology was associated with incidentally discovered primary ovarian paraganglioma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Intravesical BCG is a standard adjuvant treatment for carcinoma in situ with 75% induced cystitis as a local side effect. The International Bladder Cancer Group's recommendation for BCG cystitis included many agents, these treatment options had very limited outcomes. The existence of paraganglioma in the female genital tract described rarely &lt;1% in the vagina, uterus, vulva and ovary with only few reports. The same as paraganglioma small cell differentiation of vesical urothelial tumor is a rare entity with no reported cases of simultaneous occurrence and to differentiate each other as primary or metastatic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Bladder Botox\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injection could be offered as a treatment for overactive bladder-like symptoms in malignant cystitis. Neuroendocrine tumors are with a rare entity could be happened instantaneously in urogenital tract.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2019.03.026","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T13:20:44Z","timestamp":1553779244000},"page":"122-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Concomitant primary ovarian paraganglioma neuroendocrinal differentiated urothelial tumor in a BOTOX-injected bladder"],"prefix":"10.1097","volume":"57","author":[{"given":"M.A.","family":"Elbaset","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelwahab","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Abd Elhameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S.","family":"El-Hefnawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-33-20260114","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin"},{"key":"R2-33-20260114","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2009.01.002","article-title":"The updated EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"55","author":"Stenzl","year":"2009","journal-title":"Eur. Urol"},{"key":"R3-33-20260114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate-and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur. Urol"},{"key":"R4-33-20260114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"R5-33-20260114","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cncr.20456","article-title":"Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients","volume":"101","author":"Cheng","year":"2004","journal-title":"Cancer"},{"key":"R6-33-20260114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1066896914526779","article-title":"Ovarian paraganglioma","volume":"23","author":"Schuldt","year":"2015","journal-title":"Int. J. Surg. Pathol"},{"key":"R7-33-20260114","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijsu.2018.10.028","article-title":"The SCARE 2018 statement: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"60","author":"Agha","year":"2018","journal-title":"Int. J. Surg"},{"key":"R8-33-20260114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol"},{"key":"R9-33-20260114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","article-title":"Bacillus Calmette-Gu\u00e9rin treatment of non-muscle invasive bladder cancer","volume":"18","author":"Sylvester","year":"2011","journal-title":"Int. J. Urol"},{"key":"R10-33-20260114","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol"},{"key":"R12-33-20260114","first-page":"1","article-title":"Small cell carcinoma of the urinary bladder. A report of two cases with complete remission and a comprehensive literature review with emphasis on therapeutic decisions","volume":"5","author":"Angulo","year":"1996","journal-title":"J. Urol. Pathol"},{"key":"R13-33-20260114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.pai.0000213106.12731.d7","article-title":"Small cell carcinoma of the urinary bladder\u2014histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis","volume":"15","author":"Wang","year":"2007","journal-title":"Appl. Immunohistochem. Mol. Morphol"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261219301439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261219301439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01612930-201957000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:14:07Z","timestamp":1768396447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01612930-201957000-00033"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":12,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2019.03.026","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}